Comparative Study of Factor Xa Fluorogenic Substrates and Their Influence on the Quantification of LMWHs by Castro-Lopez, Vanessa et al.
Technological University Dublin 
ARROW@TU Dublin 
Articles School of Biological Sciences 
2010 
Comparative Study of Factor Xa Fluorogenic Substrates and Their 
Influence on the Quantification of LMWHs 
Vanessa Castro-Lopez 
CIC microGUNE 
Leanne F. Harris 
Technological University Dublin, leanne.harris@tudublin.ie 
James S. O'Donnell 
Trinity College Dublin 
Anthony J. Killard 
University of the West of England 
Follow this and additional works at: https://arrow.tudublin.ie/scschbioart 
 Part of the Biology Commons 
Recommended Citation 
Castro-Lopez, V., Harris, L., O'Donnell, J. and Killard, A. (2011). Comparative study of Factor Xa fluorogenic 
substrates and their influence on the quantification of LMWHs. ,Analytical and Bioanalytical Chemistry, 
2011 Jan;399(2):691-700. doi:10.1007/s00216-010-4314-3 
This Article is brought to you for free and open access by 
the School of Biological Sciences at ARROW@TU Dublin. 
It has been accepted for inclusion in Articles by an 
authorized administrator of ARROW@TU Dublin. For more 
information, please contact 
yvonne.desmond@tudublin.ie, arrow.admin@tudublin.ie, 
brian.widdis@tudublin.ie. 
This work is licensed under a Creative Commons 
Attribution-Noncommercial-Share Alike 3.0 License 
After online publication, subscribers (personal/institutional) to this journal will have
access to the complete article via the DOI using the URL:
If you would like to know when your article has been published online, take advantage
of our free alert service. For registration and further information, go to:
http://www.springerlink.com.
Due to the electronic nature of the procedure, the manuscript and the original figures
will only be returned to you on special request. When you return your corrections,
please inform us, if you would like to have these documents returned.
Dear Author
Here are the proofs of your article.
• You can submit your corrections online, via e-mail or by fax.
• For online submission please insert your corrections in the online correction form.
Always indicate the line number to which the correction refers.
• You can also insert your corrections in the proof PDF and email the annotated PDF.
• For fax submission, please ensure that your corrections are clearly legible. Use a fine
black pen and write the correction in the margin, not too close to the edge of the page.
• Remember to note the journal title, article number, and your name when sending your
response via e-mail or fax.
• Check the metadata sheet to make sure that the header information, especially author
names and the corresponding affiliations are correctly shown.
• Check the questions that may have arisen during copy editing and insert your
answers/corrections.
• Check that the text is complete and that all figures, tables and their legends are included.
Also check the accuracy of special characters, equations, and electronic supplementary
material if applicable. If necessary refer to the Edited manuscript.
• The publication of inaccurate data such as dosages and units can have serious
consequences. Please take particular care that all such details are correct.
• Please do not make changes that involve only matters of style. We have generally
introduced forms that follow the journal’s style.
• Substantial changes in content, e.g., new results, corrected values, title and authorship are
not allowed without the approval of the responsible editor. In such a case, please contact
the Editorial Office and return his/her consent together with the proof.
• If we do not receive your corrections within 48 hours, we will send you a reminder.
• Your article will be published Online First approximately one week after receipt of your
corrected proofs. This is the official first publication citable with the DOI. Further
changes are, therefore, not possible.
• The printed version will follow in a forthcoming issue.
Please note
http://dx.doi.org/10.1007/s00216-010-4314-3
AUTHOR'S PROOF!
Metadata of the article that will be visualized in OnlineFirst 
 
 
 
  
1 Article Title Comparative study of Factor Xa fluorogenic substrates and their 
influence on the quantification of LMWHs 
2 Article Sub- Title 
3 Article Copyright - 
Year 
Springer-Verlag 2010 
(This will be the copyright line in the final PDF) 
4 Journal Name Analytical and Bioanalytical Chemistry 
5 
Corresponding 
Author 
Family Name Killard 
6 Particle 
7 Given Name Anthony J. 
8 Suffix 
9 Organization Dublin City University 
10 Division Biomedical Diagnostics Institute, National Centre for 
Sensor Research 
11 Address Dublin 9 , Ireland 
12 e-mail tony.killard@dcu.ie 
13 
Author 
Family Name Castro-López 
14 Particle 
15 Given Name Vanessa 
16 Suffix 
17 Organization Dublin City University 
18 Division Biomedical Diagnostics Institute, National Centre for 
Sensor Research 
19 Address Dublin 9 , Ireland 
20 e-mail 
21 
Author 
Family Name Harris 
22 Particle 
23 Given Name Leanne F. 
24 Suffix 
25 Organization Dublin City University 
26 Division Biomedical Diagnostics Institute, National Centre for 
Sensor Research 
27 Address Dublin 9 , Ireland 
28 e-mail 
29 Family Name O’Donnell 
30 Particle 
31 Given Name James S. 
32 Suffix 
Page 1 of 2Springer Metadata to PDF File
10/15/2010file://C:\WMS\Springer\Metadata2PDF\temp\HAB04314.htm
AUTHOR'S PROOF!
33 
Author 
Organization Dublin City University 
34 Division Biomedical Diagnostics Institute, National Centre for 
Sensor Research 
35 Address Dublin 9 , Ireland 
36 Organization National Centre for Hereditary Coagulation Disorders, 
St. James’s Hospital 
37 Division Haemostasis Research Group, Trinity College Dublin 
38 Address Dublin 8 , Ireland 
39 e-mail 
40 
Schedule 
Received 18 August 2010 
41 Revised 6 October 2010 
42 Accepted 7 October 2010 
43 Abstract Low molecular weight heparins (LMWHs) are recognised as the preferred 
anticoagulants in the prevention and treatment of venous thromboembolism. 
Anti-Factor Xa (anti-FXa) levels are used to monitor the anticoagulant effect of 
LMWHs and such assays are routinely employed in hospital diagnostic 
laboratories. In this study, a fluorogenic anti-FXa assay was developed using a 
commercially available fluorogenic substrate with an attached 6-amino-1-
naphthalene-sulfonamide (ANSN) fluorophore and was used for the 
determination of two LMWHs, enoxaparin and tinzaparin and the heparinoid, 
danaparoid. The assay was based on the complexation of heparinised plasma 
with 100 nM exogenous FXa and 25 µM of the fluorogenic substrate Mes-D-
LGR-ANSN (C2H5)2 (SN-7). The assay was tested with pooled plasma samples 
spiked with anticoagulant concentrations in the range 0–1.6 U mL−1. The 
statistically sensitive assay range was 0–0.4 U mL−1 for enoxaparin and 
tinzaparin and 0–0.2 U mL−1 for danaparoid, with assay variation typically 
below 10.5%. This assay was then compared with a previously published 
fluorogenic anti-FXa assay developed with the peptide substrate, 
methylsulfonyl-d-cyclohexylalanyl-glycyl-arginine-7-amino-4-methylcoumarin 
acetate (Pefafluor FXa). Both assays were compared in terms of fluorescence 
intensity, lag times and sensitivity to anticoagulants. 
44 Keywords 
separated by ' - ' 
FXa - Fluorogenic substrate - AMC - ANSN - Low molecular weight heparins - 
Danaparoid 
45 Foot note 
information 
This paper was published in the special issue Heparin Characterization with 
Guest Editor Cynthia K. Larive. 
 
Page 2 of 2Springer Metadata to PDF File
10/15/2010file://C:\WMS\Springer\Metadata2PDF\temp\HAB04314.htm
AUTHOR'S PROOF!
U
N
C
O
R
R
EC
TE
D
PR
O
O
F
1
2
3 ORIGINAL PAPER
4 Comparative study of Factor Xa fluorogenic substrates
5 and their influence on the quantification of LMWHs
6 Vanessa Castro-López & Leanne F. Harris &
7 James S. O’Donnell & Anthony J. Killard
8 Received: 18 August 2010 /Revised: 6 October 2010 /Accepted: 7 October 2010
9 # Springer-Verlag 2010
10
11 Abstract Low molecular weight heparins (LMWHs) are
12 recognised as the preferred anticoagulants in the prevention
13 and treatment of venous thromboembolism. Anti-Factor Xa
14 (anti-FXa) levels are used to monitor the anticoagulant effect
15 of LMWHs and such assays are routinely employed in
16 hospital diagnostic laboratories. In this study, a fluorogenic
17 anti-FXa assay was developed using a commercially
18 available fluorogenic substrate with an attached 6-amino-1-
19 naphthalene-sulfonamide (ANSN) fluorophore and was used
20 for the determination of two LMWHs, enoxaparin and
21 tinzaparin and the heparinoid, danaparoid. The assay was
22 based on the complexation of heparinised plasma with
23 100 nM exogenous FXa and 25 μM of the fluorogenic
24 substrate Mes-D-LGR-ANSN (C2H5)2 (SN-7). The assay
25 was tested with pooled plasma samples spiked with
26 anticoagulant concentrations in the range 0–1.6 U mL−1.
27 The statistically sensitive assay range was 0–0.4 U mL−1 for
28 enoxaparin and tinzaparin and 0–0.2 U mL−1 for danaparoid,
29 with assay variation typically below 10.5%. This assay was
30 then compared with a previously published fluorogenic anti-
31 FXa assay developed with the peptide substrate,
32 methylsulfonyl-D-cyclohexylalanyl-glycyl-arginine-7-amino-
334-methylcoumarin acetate (Pefafluor FXa). Both assays were
34compared in terms of fluorescence intensity, lag times and
35sensitivity to anticoagulants.
36Keywords FXa . Fluorogenic substrate . AMC . ANSN .
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38Introduction
39Low molecular weight heparins (LMWHs) are efficacious
40anticoagulants administered for both the prophylaxis and
41treatment of venous and arterial thromboembolic disorders
42and acute coronary syndromes [1–3]. LMWHs require less
43laboratory monitoring than unfractionated heparin (UFH) as
44they exhibit a more predictable pharmacokinetic response
45with reduced bleeding risk [4]. However, clinical situations
46do arise where the anticoagulant effect of LMWHs is
47unpredictable. As a result, laboratory monitoring of
48LMWHs is necessary in special patient cohorts including
49pregnant women, the elderly, children, patients with renal
50insufficiency, and patients at the extremes of body weight
51[2, 5].
52The recommended test for monitoring LMWHs therapy
53is the anti-Factor Xa (anti-FXa) assay due to the strong
54inhibition of FXa by LMWHs [5]. The first anti-FXa assay
55was a clotting time test based on the heparin-accelerated
56inhibition of FXa [6]. Anti-FXa assays currently employed
57in the central laboratory setting are chromogenic and use a
58synthetic FXa peptide substrate coupled to a cleavable
59chromophore [7] and [2]. The application of synthetic
60peptide substrates to the analysis of coagulation proteins
61confers many advantages over traditional clot-based assays,
62in terms of greater sensitivity, specificity, accuracy, and
63simplicity [8].
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64 The endopeptidases involved in coagulation and fibrino-
65 lysis are trypsin-like serine endopeptidases [9]. Research
66 into the use of synthetic substrates for the evaluation of
67 coagulation endopeptidases began in the 1950s and 1960s.
68 Initially, chromogenic substrates based on the chromophore
69 p-nitroaniline were developed for thrombin, plasmin, and
70 trypsin analysis [8, 10], followed by the development of
71 assays using fluorogenic substrates for thrombin [11, 12].
72 Once the specific peptide cleavage sequence was known,
73 these developments were rapidly extended to other coagu-
74 lation proteins in the 70s and 80s, resulting in a new
75 strategy for the biochemical study of the coagulation
76 system [10].
77 Factor Xa occupies a critical position in the coagulation
78 cascade; hence its joint popularity with thrombin as a
79 therapeutic target for anticoagulant therapy. The first
80 photometric anti-FXa assay was introduced in 1976 [13]
81 followed by the rapid development of more specific
82 chromogenic substrates and eventually a fluorogenic
83 substrate specific for FXa which was introduced in 1977
84 [14]. Both chromogenic and fluorogenic assays are well
85 suited to the measurement of heparin, as there is a direct
86 relationship between the functional activity of heparin and
87 its effect on antithrombin allowing for greater precision in
88 its determination [8]. Fluorescence-based measurements
89 offer further advantages over colorimetric assays, such as
90 superior sensitivity and specificity [14, 15], as well as
91 measurement in a broader range of sample types such as
92 platelet poor plasma, platelet rich plasma, and whole blood
93 [16, 13].
94 Two fluorophores are principally used in commercial
95 substrates for the analysis of coagulation proteins,
96 namely 7-amino-4-methylcoumarin (AMC) and 6-amino-
97 1-naphthalene-sulfonamide (ANSN) [17, 18, 19, 20]. The
98 majority of studies have focussed on the reactivity of
99 substrates containing 7-amino-4-methylcoumarin, as it is
100 the most common fluorogenic leaving group used in
101 bioassays [21]. Coumarins can be described as a broad class
102 of fluorophores resulting in UV or near-UV excitation
103 wavelengths with a high quantum yield and low extinction
104 coefficient [22]. The naphthalenesulfonamides were reported
105 in 1992 as a new fluorescent group for substrates of
106 amidases which are also excited in the UV range. Their high
107 quantum yield and the presence of a sulfonyl moiety allows
108 for a range of chemical modifications which can enhance
109 enzymatic substrate specificity [9]. However, given the
110 availability of these substrates, few publications have
111 evaluated their usefulness in the development of anti-FXa
112 assays.
113 A novel fluorogenic anti-FXa assay was developed in
114 this study using a peptide substrate for FXa with an
115 attached ANSN fluorophore and was compared to a
116 previously developed assay based on an AMC fluorescent
117leaving group [16]. A comparison of assay responses to
118pharmacological concentrations of LMWHs and danaparoid
119in commercial pooled plasma is reported.
120Materials and methods
121Reagents
122Water (ACS reagent) and HEPES (minimum 99.5%
123titration) were purchased from Sigma-Aldrich (Dublin,
124Ireland). Filtered HEPES was prepared at a concentration
125of 10 mM (pH 7.4). A 100 mM filtered stock solution of
126CaCl2 from Fluka BioChemika (Buchs, Switzerland) was
127prepared from a 1 M CaCl2 solution. The fluorogenic
128substrate methylsulfonyl-D-cyclohexylalanyl-glycyl-arginine-
1297-amino-4-methylcoumarin acetate (Pefafluor FXa) was
130purchased from Pentapharm (Basel, Switzerland). It was
131reconstituted in 1 mL of water having a final concentration of
13210 mM, aliquoted and stored at −20 °C. Dilutions from
13310 mM stock solutions down to 10 μM were freshly prepared
134with water when needed. Subsequent dilutions were prepared
135in 10 mM HEPES. Tubes were covered with aluminium foil
136to protect from exposure to light. The fluorogenic substrate
137Mes-D-LGR-ANSN (C2H5)2 (SN-7), containing the fluores-
138cent reporter group ANSN, was acquired from Haematologic
139Technologies Inc. (Vermont, USA). Stock solutions of
14010 mM in DMSO were stored at −20 °C and also protected
141from light with aluminium foil. Dilutions of stock solutions
142were performed with 10 mM HEPES. Table 1 summarises
143the kinetic constants and physico-chemical properties of
144both the Pefafluor FXa and SN-7 fluorogenic substrates.
145These parameters were obtained from the suppliers.
146Kinetic constants refer to the cleavage of both fluorogenic
147substrates by the endopeptidase FXa. Purified human FXa
148(serine endopeptidase; code number: EC 3.4.21.6) was
149obtained from HYPHEN BioMed (Neuville-Sur-Oise,
150France). Tinzaparin (Innohep®) was obtained from LEO
151Pharma (Ballerup, Denmark). Enoxaparin (Clexane®) and
152danaparoid (Orgaran®) were from Sanofi-Aventis (Paris,
153France) and Schering-Plough (New Jersey, USA), respec-
154tively. Human pooled plasma was purchased from Helena
155Biosciences Europe (Tyne and Wear, UK). Lyophilised
156plasma was reconstituted in 1 mL of water and left to
157stabilise for at least 20 min at room temperature prior to
158use.
159Apparatus and software
160Fluorescence intensities were measured on an Infinite
161M200 microplate reader from Tecan Group Ltd. (Männe-
162dorf, Switzerland) equipped with a UV Xenon flashlamp.
163Flat, black-bottom 96-well polystyrol FluorNunc™ micro-
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164 plates from Thermo Fisher Scientific (Roskilde, Denmark)
165 were used.
166 Fluorogenic anti-FXa assay
167 Measurements were carried out in reconstituted citrated
168 human pooled plasma. FXa and the ANSN-based fluoro-
169 genic substrate were titrated within the range of 0.1–
170 100 nM and 8.3–33.3 μM (Km=125 μM), respectively.
171 Samples consisting of 6.25 μL of 100 mM CaCl2, 43.75 μL
172 of pooled plasma, and 50 μL of FXa (0.1–100 nM) were
173 incubated at 37 °C for 3 min and shaken for the first 150 s.
174 The reaction was started by adding 50 μL of ANSN-based
175 fluorogenic substrate (8.3–33.3 μM). Samples within wells
176 were mixed with the aid of orbital shaking at 37 °C for
177 30 s. Finally, immediately after shaking, fluorescence
178 measurements were recorded at 37 °C for 60 min with
179 integration time of 20 μs. Fluorescence excitation was at
180 352 nm and emission was monitored at 470 nm,
181 corresponding to the excitation/emission wavelengths of
182 the ANSN fluorophore. All measurements were carried out
183 in triplicate. Following optimization of assay conditions,
184 pooled commercial plasma samples were spiked with
185 pharmacologically relevant concentrations (0–1.6 U mL−1)
186 of therapeutic anticoagulants including enoxaparin, tinza-
187 parin, and danaparoid. The reaction rate (slope), which is
188 defined as the change in fluorescence divided by the change
189 in time (i.e., dF/dt), was measured as the linear portion of
190 the fluorescence response profile and plotted versus
191 anticoagulant concentration. The assay using the Pefafluor
192 FXa fluorogenic substrate was optimised as previously
193described by Harris et al. [16]. The fluorescence excitation
194and emission wavelengths were 342 nm and 440 nm,
195respectively, corresponding to the excitation/emission
196wavelengths of the AMC fluorophore. The only difference
197between these assays was the insertion of an incubation
198step in the ANSN-based assay to improve reproducibility.
199Statistical analysis
200All graphs were plotted using SigmaPlot 8.0. and SPSS
20117.0 was used for statistical analysis. Intra-assay differences
202within the anticoagulant concentration range were com-
203pared using one-way analysis of variance (ANOVA), with
204subsequent post-hoc analysis performed (Scheffe’s test) if
205significance was observed. A result of p<0.05 was
206considered statistically significant. Inter-assay differences
207between the two fluorogenic substrates employed were
208statistically analysed using the paired Student’s t test at a
209significance level of 5%.
210Results
211Assay optimisation
212In this study, two fluorogenic substrates with two different
213fluorophore leaving groups were compared using the anti-
214FXa assay principle, whereby exogenous FXa added to
215heparinised plasma was inhibited by the heparin–AT
216complex and the resulting FXa activity was measured using
217fluorescence. A new assay is reported that measures the rate
t1.1 Table 1 Kinetic constants and physico-chemical properties of both fluorogenic substrates
H2N
SO2N(C2H5)2
H2N O o
Fluorogenic substrate SN-7 Pefafluor FXa
Formula Mes-D-LGR-ANSN(C2H5)2 CH3SO2-D-CHA-Gly-Arg-
AMC.AcOH
Physical form Liquid Lyophilised powder
Fluorophore chemical structure
Mw (g mol-1) 682.8 679.8
Km (µM) 125 220
kcat (s-1) 36 162
kcat/Km (M-1 s-1) 290,000 ~740,000
Wavelength maxima (nm) 352 (λex), 470 (λem) 342 (λex), 440 (λem)
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218 of ANSN fluorophore release as a result of FXa substrate
219 cleavage and is compared to the rate of AMC fluorophore
220 release which has been published previously [16]. Opti-
221 mised assay concentrations for this new fluorogenic assay
222 were determined by performing titrations of FXa from 0.1
223 to 100 nM and fluorogenic substrate concentrations from
224 8.3 to 33.3 μM. To allow for differentiation in the assay
225 reaction rates, the concentration range of the ANSN-based
226 substrate was selected so that it was lower than the Km
227 value. The final working assay concentrations of 25 μM
228 ANSN-based fluorogenic substrate and 100 nM FXa,
229 conform to the optimisation criteria which included short
230 lag times, fast reaction rates, and a broad fluorescence
231 dynamic range for the differentiation of anticoagulant
232 concentrations. The same criteria were also selected for
233 the optimization of the AMC-based fluorogenic anti-FXa
234 assay.
235 Evaluation of the ANSN-based anti-FXa fluorogenic assay
236 Three anticoagulant drugs were tested using the fluorogenic
237 anti-FXa assay with the ANSN-based substrate in commer-
238 cial pooled plasma.
239 The fluorescence intensity profiles over time for tinza-
240 parin plasma samples in the fluorogenic anti-FXa assay can
241 be seen in Fig. 1 and the inset shows the dose–response
242 profile versus anticoagulant concentration. As the concen-
243 tration of tinzaparin increased, the fluorescence profiles
244 reached lower fluorescence intensity values after 1 h. In the
245 absence of tinzaparin, the maximum intensity value was
246 56,000 AU; with 0.2 U mL−1 the profile reached
247 40,000 AU and 27,000 AU for 0.4 U mL−1. From 0.4 to
248 1.6 U mL−1, the maximum fluorescence intensity value was
249 between 22,000 and 27,000 AU.
250Lag times were calculated by extrapolation of the
251linear portion of the progression curve to its intersection
252with the x-axis [23]. In the presence of higher anticoag-
253ulant concentrations, longer lag time values were ob-
254served. At low concentrations of 0 and 0.2 U mL−1
255tinzaparin, the reaction was very quick and no lag
256time was observed. Lag times increased to 310 and
257630 s for 0.4 U mL−1 and 0.6 U mL−1 respectively. At
258concentrations of 0.8–1.6 U mL−1 lag time values were
2591,010 s.
260The reaction rates of the fluorescence profiles were
261calculated to generate dose–response profiles and a similar
262trend was observed for all drugs analysed, in that as
263anticoagulant concentration increased, the rate of the
264reaction decreased. The slope values were statistically
265different up to 0.4 U mL−1 (p<0.003) with significantly
266reduced sensitivity in the upper tinzaparin range (0.6–
2671.6 U mL−1).
268The anti-FXa assay was also tested with enoxaparin,
269another member of the low molecular weight heparin
270family. The fluorescence profiles are very similar to those
271of tinzaparin (Fig. 2). The fluorescence profiles for
2720 U mL−1 reached 52,000 AU after 1 h, for 0.2 U mL−1
273the intensity value was 38,000 AU and with 0.4 U mL−1 the
274profile reached 28,000 AU. At higher enoxaparin concen-
275trations, the profiles reached maximum intensity values of
27621,000 and 28,000 AU.
277At low concentrations of enoxaparin lag times were
278absent but were calculated as 110 s for 0.4 and 0.6 U mL−1
279enoxaparin. At higher concentrations, lag times increased to
280590 s for 0.8 and 1 U mL−1, 730 s for 1.2 U mL−1, and
281910 s for 1.4 and 1.6 U mL−1.
282The dose–response curve calculated from the linear
283slopes of the fluorescence profiles of enoxaparin can be
Fig. 1 Fluorescence intensity
vs. time for the anti-FXa activity
with tinzaparin (n=3). Tinza-
parin concentration increases
from top to bottom. Inset Dose–
response calibration curve of
tinzaparin in pooled plasma in
the ANSN-based fluorogenic
anti-FXa assay (n=3), calculated
from the linear slopes (dF/dt) of
the fluorescence response curves
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284 seen in Fig. 2 and good sensitivity was achieved with
285 concentrations up to 0.4 U mL−1 (p<0.003).
286 Figure 3 shows the fluorescence profiles of the anti-Xa
287 assay in the presence of danaparoid. The fluorescence
288 profile for 0 U mL−1 reached 55,000 AU after 1 h, at
289 0.2 U mL−1 the maximum fluorescence intensity value was
290 35,000 AU and from 0.4 to 1.6 U mL−1 danaparoid,
291 profiles reached fluorescence intensities between 22,000
292 and 29,000 AU.
293 Similar to the LMWHs, lag times were not observed at
294 low concentrations of danaparoid. Lag times increased
295 from 200 s at 0.4 U mL−1 to 780 s at 0.6 U mL−1, 1,050 s
296 at 0.8 U mL−1 and 1180 s at 1 U mL−1. At 1.2 U mL−1 and
297 1.6 U mL−1 danaparoid lag times were 1,320 s and at
298 1.4 U mL−1 the lag time was calculated as 1,480 s.
299Inset of Fig. 3 shows the dose–response calibration curve
300of danaparoid in the fluorogenic anti-FXa assay. Statistical
301analysis returned significant differences in the variances
302with the Levene’s test (p=0.011), so one-way ANOVA
303could not be applied. When equal variances were not
304assumed, the Tamhane test returned significant differences
305between 0 and 0.2 U mL−1 danaparoid (p=0.031).
306The reaction rates were compared for all drugs tested
307using the normalised data (ratios of the dose–responses
308against the averaged dose–response value at 0 U mL−1). The
309reaction rates for enoxaparin were higher than tinzaparin
310rates at all concentrations from 0 to 1.6 U mL−1. Both low
311molecular weight heparins returned higher reaction rates than
312danaparoid in the statistically sensitive range of 0–
3130.2 U mL−1. Enoxaparin reaction rates were the highest of
Fig. 2 Fluorescence intensity
vs. time for the anti-FXa activity
with enoxaparin (n=3). Enoxa-
parin concentration increases
from top to bottom. Inset Dose–
response calibration curve of
enoxaparin in pooled plasma in
the ANSN-based fluorogenic
anti-FXa assay (n=3), calculated
from the linear slopes (dF/dt) of
the fluorescence response curves
Fig. 3 Fluorescence intensity
vs. time for the anti-FXa activity
with danaparoid (n=3). Dana-
paroid concentration increases
from top to bottom. Inset Dose–
response calibration curve of
danaparoid in pooled plasma in
the ANSN-based fluorogenic
anti-FXa assay (n=3), calculated
from the linear slopes (dF/dt) of
the fluorescence response curves
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314 all drugs tested and only at concentrations of 0.6, 0.8, and
315 1 U mL−1, were tinzaparin reaction rates lower than
316 danaparoid, but these fall into the statistically insensitive
317 range.
318 The analytical errors (standard deviation and percentage
319 coefficient of variation) related to each of the slope
320 measurements for all three anticoagulants were calculated.
321 All CV values were <10.5% with the exception of
322 0.2 U mL−1 tinzaparin which returned a CV value of 21%.
323 Comparative studies of AMC versus ANSN-based
324 fluorogenic assays
325 The two synthetic peptide substrates containing two
326 different fluorogenic leaving groups were compared in
327 terms of their fluorescence intensity, lag times, and slope
328 values.
329 Fluorescence intensity
330 All three of the AMC-based fluorogenic assay reaction
331 progress curves for enoxaparin, tinzaparin, and danaparoid,
332 reported by Harris et al. [16], approached a similar
333 maximum plateau value of product formation at approx-
334 imately the same level (i.e., 48,000–53,000 AU) indepen-
335 dent of anticoagulant type and concentration. This is an
336 indication of substrate depletion and also that the enzyme
337 remains stable under the conditions tested. In the ANSN-
338 based study, the maximum value of product formed for all
339 three anticoagulant drugs reached different fluorescence
340 intensity values depending on anticoagulant concentration.
341 As the concentration of anticoagulant increased from 0 to
342 1.6 U mL−1, the fluorescence intensity values decreased
343 from 56,000 to 22,000 for tinzaparin, 52,000 to 21,000 for
344 enoxaparin and finally, from 55,000 to 22,000 for
345 danaparoid.
346 Lag time values
347 The increase in lag time with increasing anticoagulant
348 concentration was common to both fluorogenic assays
349 as shown in Table 2. Furthermore, the ANSN-based
350 anti-FXa fluorogenic assay returned smaller lag time
351 values than the AMC-based assay for all anticoagulant
352 concentrations.
353 Slope values
354 Analysis of slope values at 0 U mL−1 returned 25%
355 variation in all assays. As a result, all slope values were
356 normalised with respect to those at 0 U mL−1 for each
357 anticoagulant. As can be seen in Fig. 4, the fluorogenic
358 anti-FXa assay using the AMC fluorogenic substrate
359returned higher slopes than the ANSN fluorogenic assay
360in all instances. The inter-assay variability between the two
361fluorogenic substrates for each anticoagulant drug was
362statistically evaluated using the paired Student’s t test.
363Results indicate that there is a significant mean difference
364(p<0.05) between the two fluorogenic anti-FXa assays for
365each anticoagulant at all concentrations, except for
3660 U mL−1 as it corresponds to the unit value of normal-
367isation in all cases.
368Assay sensitivity
369The intra-assay variability between different concentrations
370of anticoagulants was assessed for both fluorogenic
371substrates. Table 3 outlines the statistically sensitive range
372for both fluorogenic anti-FXa assays each containing a
373different leaving group in the presence of tinzaparin,
374enoxaparin, and danaparoid. When the ANSN-based fluo-
375rogenic anti-FXa assay was performed in the presence of
376tinzaparin, the slopes of the enzymatic reaction were
377statistically different up to 0.4 U mL−1 (p<0.05) at intervals
378of 0.2 U mL−1. In the case of the Pefafluor FXa substrate
379the assay proved to be sensitive up to 0.6 U mL−1
380tinzaparin (p<0.001). This reduction in assay sensitivity
381for the ANSN-based fluorogenic anti-FXa assay was also
382observed for enoxaparin. The fluorogenic anti-FXa assay
383using the ANSN-based substrate resulted in a narrower
384statistically sensitive range from 0 to 0.4 U mL−1 (p<0.05)
385when compared with the AMC-based substrate assay range
386of 0–0.8 U mL−1 (p<0.001) for enoxaparin. The effect of
387danaparoid was also evaluated in both fluorogenic assays
388and a larger difference in assay sensitivity was observed.
389Response slopes to danaparoid concentrations at
3900.2 U mL−1 intervals were statistically different up to
3910.2 U mL−1 and 1 U mL−1 for the ANSN and AMC-based
392substrate assays, respectively. In all cases, the AMC-based
393substrate seems to offer a wider assay sensitive range
394compared with the ANSN-based fluorogenic substrate
395when quantifying both LMWHs and danaparoid.
396Reproducibility (%CV values)
397Reproducibility of the two developed assays was deter-
398mined using the percentage coefficient of variation (%CV).
399Comparing CV values between the two fluorogenic assays,
400results in lower variation for both low molecular weight
401heparins and danaparoid with the AMC fluorophore.
402Studies of precision for the fluorogenic anti-FXa assay
403using the AMC-based substrate showed a coefficient of
404variation ranging between 0.5% and 7% [16]. In the case of
405the ANSN-based assay, CV values were below 10.5%
406except for 0.2 U mL−1 tinzaparin which returned a CV of
40721%.
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409 FXa is a serine endopeptidase which occupies a central role
410 in the coagulation cascade. LMWHs are anticoagulant
411 drugs used in the treatment of thrombosis and cardiovas-
412 cular diseases and can effectively neutralise FXa to prevent
413 bleeding [24]. At present, commercially available anti-FXa
414 tests capable of measuring LMWHs within the therapeutic
415 range are all chromogenic assays. While chromogenic anti-
416 FXa assays have some advantages over traditional clot-
417 based assays, they do still suffer from some drawbacks as
418 highlighted by Harris et al. [16]. To counteract these
419 limitations, they presented a new fluorogenic anti-FXa
420 assay based on the AMC fluorogenic substrate which can
421 differentiate and quantify UFH, enoxaparin, tinzaparin, and
422 danaparoid within the therapeutic range and with CV values
423 below 7%.
424 A number of studies have been devoted to the
425 identification of specific FXa fluorogenic substrates with
426desirable properties, such as the photo and chemical
427stability of the generated fluorescent group, the Stokes
428shift, the solubility of substrate and fluorescent product in
429aqueous buffer, and the fluorescence quantum yield, to
430mention just a few [9]. To date, several synthetic fluoro-
431genic substrates targeting FXa have been developed with
432different peptidic groups, attached to just two fluorescent
433detecting groups namely ANSN [9] and AMC [14].
434This paper sought to develop a new fluorogenic anti-FXa
435assay using the commercially available ANSN-based fluo-
436rogenic substrate for FXa and compare it with the AMC-
437based fluorogenic anti-FXa assay previously investigated by
438Harris et al. [16] in the presence and absence of two
439LMWHs (i.e., enoxaparin and tinzaparin) and danaparoid.
440The principle of the assay is to measure the rate of
441fluorescent tag release which results from FXa proteolysis
442of the two synthetic peptide substrates, in the presence and
443absence of three anticoagulants. From the results obtained,
444different observations can be made: firstly, the anti-FXa
t2.2Conc (U mL−1) Enoxaparina (s) Tinzaparina (s) Danaparoida (s)
t2.3AMC ANSN AMC ANSN AMC ANSN
t2.40 200 0 160 0 220 0
t2.50.2 280 0 240 0 560 0
t2.60.4 420 110 380 310 800 200
t2.70.6 580 110 670 630 1,420 780
t2.80.8 850 590 900 1,010 2,010 1,050
t2.91 940 590 1,040 1,010 2,070 1,180
t2.101.2 1,020 730 1,440 1,010 2,440 1,320
t2.111.4 1,260 910 1,800 1,010 >3,600 1,480
t2.121.6 1,310 910 2,000 1,010 >3,600 1,320
t2.1 Table 2 Lag times of averaged
progress curves for both
anti-FXa fluorogenic assays in
the presence and absence of
tinzaparin, enoxaparin, and
danaparoid
a Averaged of triplicate measure-
ments (n=3)
Fig. 4 Dose–response curves
(normalised data) of the
fluorogenic: ANSN-based
anti-FXa assay to tinzaparin
(empty circle), enoxaparin
(empty upright triangle), and
danaparoid (empty square);
AMC-based anti-FXa assay to
tinzaparin (filled circle), enoxa-
parin (filled upright triangle),
and danaparoid (filled square)
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445 assay presented in this paper was statistically differentiated
446 at intervals of 0.2 up to 0.4 U mL−1 for enoxaparin and
447 tinzaparin. It was also found to be statistically sensitive for
448 danaparoid up to 0.2 U mL−1. CV values were <10.5% for
449 all anticoagulant drugs except for tinzaparin at 0.2 U mL−1,
450 which returned 21%. The sensitivity and dynamic range of
451 the fluorogenic anti-FXa assay developed in this study are
452 smaller than the values shown by the commercially
453 available chromogenic anti-FXa assays. Most of the
454 chromogenic anti-FXa assays are able to measure concen-
455 trations of LMWHs up to 1 U/ml with %CV values
456 between 5% and 10% [16].
457 Secondly, the reaction progress curves of the ANSN-
458 based assay show a very different time-course of product
459 formation compared with those of the AMC-based assay. In
460 this study, we observed a decrease in fluorophore formation
461 with increasing anticoagulant concentration. In other words,
462 the reaction progress curves reach lower fluorescence
463 intensities as the concentration of anticoagulant increases.
464 This could be indicative of inhibition by the accumulating
465 products, instability of the enzyme or some other compo-
466 nent of the assay system, the presence of enzyme-activated
467 irreversible inhibitors [25], i.e., antithrombin (ATIII) in
468 human plasma or the anticoagulants added to the assay. In
469 comparison, the AMC-based fluorogenic assay showed
470 similar maximum plateau values at all concentrations of
471 FXa inhibitors, indicating enzyme stability and fluorogenic
472 substrate depletion. Moreover, the ANSN substrate did not
473 yield as good a signal-to-noise ratio as the AMC-based
474 substrate; however, the former was not consumed as
475 rapidly.
476 Thirdly, lag time values for the ANSN-based assay were
477 shorter compared with the AMC-based assay for all
478 anticoagulants and at all concentrations. Considering that
479 the Km value for ANSN is 125 and 220 μM for AMC, it is
480 expected that the ANSN substrate would have greater
481 binding affinity for FXa (i.e., shorter lag times) than the
482 AMC substrate. It has been suggested by Butenas et al. [9]
483 that this is due to the limited possibility for modification of
484 the AMC group. The lack of an adequate functional group
485 does not allow for optimisation of substrate interaction
486 compared to the presence of a modifiable sulfonyl moiety
487in the ANSN group which can enhance substrate specific-
488ity. Additionally, lag times were found to increase with
489increasing anticoagulant concentration. This shows the
490ability of FXa inhibitors to form a complex with ATIII
491and FXa. Any FXa not neutralised is free to react with the
492fluorogenic substrates; therefore lag times can be due to the
493time taken for the concentrations of the intermediate
494enzyme–substrate and enzyme–product complexes to rise
495to their steady-state levels [25].
496And finally, the rates of the enzymatic reaction (i.e., rate
497of fluorophore formation) were higher for the AMC-based
498fluorogenic anti-FXa assay in all cases. In the presence of
499enoxaparin the AMC-based fluorogenic assay resulted in
500reaction rates that were between 3.6- and 4.8-fold higher
501than the ANSN assay except for 0.2 U mL−1 which was
5021.8-fold higher. Tinzaparin reaction rates were between 2.3-
503and 8.4-fold higher than ANSN rates, and finally, danapa-
504roid resulted in rates of reaction that were 2.6- to 5.1-fold
505higher than those in the ANSN assay. This behaviour is
506related to the catalytic constant (kcat) values of FXa with
507respect to the two synthetic peptide substrates. The kcat
508value for the ANSN substrate is 36 and 162 s−1 for the
509AMC substrate. Thus, the higher the kcat value, the faster
510the enzyme–substrate complex conversion to fluorophore.
511Hence, these values indicate that FXa should convert the
512AMC-based fluorogenic substrate into its fluorophore 4.5-
513fold quicker than the ANSN-based fluorogenic substrate.
514This explanation is consistent with our findings.
515In terms of assay sensitivity and reproducibility, the
516AMC-based substrate offers a wider assay sensitive range
517for enoxaparin, tinzaparin, and danaparoid compared with
518the ANSN detecting group in the fluorogenic anti-FXa
519assay. The ANSN-based (AMC-based) assay resulted in
520detection ranges of 0–0.4 U mL−1 (0–0.8 U mL−1) for
521enoxaparin, 0–0.4 U mL−1 (0–0.6 U mL−1) for tinzaparin,
522and 0–0.2 U mL−1 (0–1 U mL−1) for danaparoid. In
523addition, assay reproducibility for both LMWHs and
524danaparoid when using the ANSN-based substrate was
525<10.5%, while the AMC-based substrate returned CVs of
526<7%.
527Assay sensitivity as well as assay precision can also be
528analysed in terms of the kcat/Km (“specificity constant”)
529values of FXa with respect to the two fluorogenic
530substrates. FXa has a kcat/Km of 290,000 M
−1 s−1 for the
531ANSN fluorogenic substrate and ∼740,000 M−1 s−1 for the
532AMC substrate. The importance of kcat/Km is that it
533determines the specificity of an enzyme for competing
534substrates. Therefore taking into account these two values,
535FXa shows a 2.5-fold greater specificity for AMC than for
536ANSN which translates into a wider assay sensitive range
537and better assay reproducibility. Therefore, what appears to
538be a poor substrate in terms of affinity for FXa (i.e.
539Pefafluor FXa has a relatively high Km of 220 μM
t3.1 Table 3 Comparison of the statistically sensitive range for each
anticoagulant tested in two fluorogenic anti-FXa assays based on
different fluorophore leaving groups
t3.2 Anticoagulant drug Statistically sensitive range (U mL−1)
t3.3 ANSN AMC
t3.4 Tinzaparin 0–0.4 0–0.6
t3.5 Enoxaparin 0–0.4 0–0.8
t3.6 Danaparoid 0–0.2 0–1
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540 compared with 125 μM for SN-7), it actually shows an
541 overall greater effectiveness for substrate hydrolysis.
542 However, it has been suggested by Bromfield et al. [18]
543 who performed competitive inhibition assays for FXa with
544 the fluorogenic coumarin substrate Boc-IEGR-AMC, that
545 substrates with low Km values rather than high kcat/Km
546 values may be better indicators of inhibitor potential for a
547 peptidic sequence. Nevertheless, it is a complex area of
548 research due to the open and flat architecture of the FXa
549 active site [26, 27] which results in its low selectivity for
550 peptide substrates [28].
551 Overall, fluorogenic substrates incorporating the AMC
552 leaving group are commonly used probes in proteolytic
553 assays [29], fluorogenic thrombin generation assays [30,
554 31, 32, 33, 34] and more specifically in fluorogenic FXa
555 assays [35, 36, 37, 38, 39]. The use of ANSN-based
556 fluorogenic assays has also been described, but to a lesser
557 extent for activated protein C [19], human factor VIIa and
558 factor VIIa-tissue factor [40], and lately, for the Mytilus
559 edulis anticoagulant peptide [41].
560 In summary, a new fluorogenic anti-FXa assay has been
561 investigated in human pooled plasma based on the
562 fluorescent reporter group ANSN. It was capable of
563 statistically differentiating enoxaparin up to 0.4 U mL−1,
564 tinzaparin up to 0.4 U mL−1, and danaparoid up to
565 0.2 U mL−1 with CVs of <10.5%. Moreover, it was
566 compared with the 7-amino-4-methylcoumarin-based fluo-
567 rogenic anti-FXa assay previously developed by Harris et
568 al. [16]. Results indicate that the AMC-based fluorogenic
569 anti-FXa assay is quicker, it has a wider sensitive range and
570 it is more precise than the ANSN-based fluorogenic anti-
571 FXa assay examined in this study.
572
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